Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis

McQuellon, Richard P.; Loggie, Brian W.; Fleming, Ronald A.; Russell, Greg; Lehman, A.B.; Rambo, TD

doi:10.1053/ejso.2000.1033

Cited by 155 publications

(84 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…McQuellon şi colab. [27] într-un studiu efectuat pe un lot de 64 de pacienţi operaţi pentru CP de cauză digestivă, utilizând formularele de calitatea vieţii FACT-C, a notat că imediat postoperator calitatea vieții, statusul emotional și cel fizic sunt în scădere progresivă până la 3 luni iar ulterior, se remarcă o îmbunătăţire a calităţii vieţii până la 1 an (74% din pacienţi sunt capabili la 12 luni postoperator să desfăşoare singuri peste 50% din activitatea cotidiană față de 19% din pacienți la 3 luni).…”

Section: Calitatea Vieţii După Chipunclassified

Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis From Colorectal Orgin

Huțanu¹,

Radu²,

Filip³

et al. 2013

View full text Add to dashboard Cite

Abstract): Peritoneal carcinomatosis due to gastrointestinal malignancies has been considered a poor prognosis entity. Few prospective studies have shown 6 to 12 months suvirval period for peritoneal carcinomatosis of colorectal cancer (CR) treated with systemic chemotherapy. New chemotherapeutic agents and monoclonal antibodies increased survival to 16-22 months. Despite this new systemic treatment most patients will die due to cachexia, peritonitis and/or intestinal occlusion. Normothermic or hyperthermic intraperitoneal chemotherapy, intraoperative or early postoperative became in the last three decades the standard treatment for several malignancies of peritoneum and it has proven effective in peritoneal carcinomatosis of colorectal and ovarian origin. The main drawbacks of this method is lack of studies to confirm the benefits. A long learning curve, high morbidity and mortality, lack of studies on quality of life and the high cost of this procedure appears to be the most important disadvantages of this method. Recent studies including carreful selected patients show a five year suvirval rate of 40%, median survirval period of 30 months, high morbidity (up to 60%) and a mortality up to 8%. Phase III trials on patients with peritoneal carcinomatosis from colorectal cancer treated with HlPEC are still ongoing. We present and review the latest results from the literature regarding the value of HIPEC in peritoneal carcinomatosis from colorectal origin.

show abstract

Section: Calitatea Vieţii După Chipunclassified

Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis From Colorectal Orgin

Huțanu¹,

Radu²,

Filip³

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Moreover, earlier reports on HIPEC suffered from the very small number of included patients, making any stratification impossible. However, beside their role as independent prognostic factors, tumor characteristics are mandatory to get a better stratification, given that the only outcome parameter used is the overall survival, whereas only few studies considered quality of life and PC-free survival [160][161][162] .…”

Section: Peritoneal Carcinomatosis From Colo-rectal Cancermentioning

confidence: 99%

Peritoneal Carcinomatosis

2011

Encyclopedia of Cancer

View full text Add to dashboard Cite

Several gastrointestinal and gynecological malignancies have the potential to disseminate and grow in the peritoneal cavity. The occurrence of peritoneal carcinomatosis (PC) has been shown to significantly decrease overall survival in patients with liver and/or extraperitoneal metastases from gastrointestinal cancer. During the last three decades, the understanding of the biology and pathways of dissemination of tumors with intraperitoneal spread, and the understanding of the protective function of the peritoneal barrier against tumoral seeding, has prompted the concept that PC is a loco-regional disease: in absence of other systemic metastases, multimodal approaches combining aggressive cytoreductive surgery, intraperitoneal hyperthermic chemotherapy and systemic chemotherapy have been proposed and are actually considered promising methods to improve loco-regional control of the disease, and ultimately to increase survival. The aim of this review article is to present the evidence on treatment of PC in different tumors, in order to provide patients with a proper surgical and multidisciplinary treatment focused on optimal control of their locoregional disease.© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.Key words: Carcinosis; Peritoneal; Ovarian; Gastric; Colorectal; Hipec; Intraperitoneal chemotherapy; Cytoreductive surgery; Cancer; Advanced Core tip: This review aims to present the evidence on treatment of peritoneal carcinosis in different tumors, in order to provide patients with a proper surgical and multidisciplinary treatment focused on optimal control of their locoregional disease.

show abstract

“…Early i.p. treatment with ifosfamide þ Capcellt on day 2 resulted in a significant tumor reduction (tumor volume: 9.8679.60 mm 3 The table presents the median number of tumor nodules (total and median number by size) found in mice of each group (eight mice/ group).…”

Section: Tumor Growth and Response To Treatmentmentioning

confidence: 99%

“…1,2 The subsequent malignant ascites causes significant pain and discomfort thus dramatically reducing the quality of life in these patients. 3,4 Despite continuous efforts to develop medical and surgical treatments, options are limited and most often palliative. 5 Targeted chemotherapy is a novel approach towards treatment of intraperitoneal cancer either by improving drug delivery from the site of application into the tumor cell 6 or by switching the site of the activation of a prodrug from the liver into the abdominal cavity, thereby enhancing the locoregional antitumor effect.…”

Section: Introductionmentioning

confidence: 99%

Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide

et al. 2005

View full text Add to dashboard Cite

The prognosis of peritoneal spread from gastrointestinal cancer and subsequent malignant ascites is poor, and current medical treatments available are mostly ineffective. Targeted chemotherapy with intraperitoneal prodrug activation may be a beneficial new approach. L293 cells were genetically modified to express the cytochrome P450 enzyme 2B1 under the control of a cytomegalovirus immediate early promoter. This CYP2B1 enzyme converts ifosfamide to its active cytotoxic compounds. The cells are encapsulated in a cellulose sulfate formulation (Capcellt). Adult Balb/c mice were inoculated intraperitoneally with 1 Â 10 6 colon 26 cancer cells, previously transfected with GFP to emit a stable green fluorescence, by injection into the left lower abdominal quadrant. Two or five day's later animals were randomly subjected to either i.p. treatment with ifosfamide alone or ifosfamide combined with microencapsulated CYP2B1-expressing cells. Peritoneal tumor volume and tumor viability were assessed 10 days after tumor inoculation by means of fluorescence microscopy, spectroscopy and histology. Early i.p. treatment with ifosfamide and CYP2B1 cells resulted in a complete response. Treatment starting on day 5 and single-drug treatment with ifosfamide resulted in a partial response. These results suggest that targeted i.p. chemotherapy using a combination of a prodrug and its converting enzyme may be a successful treatment strategy for peritoneal spread from colorectal cancer.

show abstract

Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis

Cited by 155 publications

References 23 publications

Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis From Colorectal Orgin

Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis From Colorectal Orgin

Peritoneal Carcinomatosis

Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide

Contact Info

Product

Resources

About